Vadodara-based biotech startup Genexis Biotech has successfully raised ₹4 crore in a seed funding round, signaling strong investor confidence in its innovative approach to protein manufacturing. The company aims to bridge a critical gap in India’s biotech sector by producing high-quality, animal-origin-free proteins at scale—a game changer for industries like biopharma, food-tech, and life sciences.
What Makes Genexis Biotech Stand Out?
Genexis is tackling one of the most pressing challenges in the biotech value chain: scalable production of animal-origin-free proteins. This approach not only addresses ethical concerns but also meets rising demand for sustainable, safe, and effective protein products across sectors.
Mihir Joshi, Managing Director of GVFL, the lead investor, said,
“Genexis’ strong R&D capabilities, robust infrastructure, and early market traction position it perfectly to cater to a growing demand in biopharma, food-tech, and life sciences.”
Strategic Partnerships and Growth
Genexis has already inked partnerships with pharmaceutical companies, biotech startups, and academic research labs. A major milestone in 2023 was signing a Memorandum of Understanding (MoU) with the Gujarat government to help scale up recombinant protein manufacturing.
The company also showcased its cutting-edge capabilities at the prestigious Global Bio-India 2024 event, gaining visibility on a national and international stage.
Future Plans and Expansion
Looking ahead, Genexis plans to:
- Develop encapsulated growth factor formulations targeted at the cosmetics industry
- Collaborate closely with Contract Development and Manufacturing Organisations (CDMOs) to broaden its market reach and accelerate product development
About GVFL — The Investors Behind Genexis
GVFL, headquartered in Ahmedabad, is one of India’s earliest venture capital firms. Having backed over 100 companies with numerous successful exits, GVFL brings deep expertise in sectors like healthtech, fintech, cleantech, and enterprise solutions.
In recent years, GVFL has increasingly focused on deeptech and biotech innovations, making the investment in Genexis a natural fit within its forward-looking portfolio.
Why This Funding Round Matters
The ₹4 crore seed funding gives Genexis the capital boost needed to expand research, refine manufacturing processes, and accelerate product launches. This round is an important step toward making India a global hub for animal-origin-free protein production—an area poised for rapid growth and massive opportunity.
Genexis Biotech’s ₹4 crore seed funding is more than just an investment—it’s a vote of confidence in India’s biotech future. With strong backing from GVFL and key government support, this Vadodara-based startup is set to redefine protein production standards and scale innovation across multiple industries.
